Abstract: Pharmaceutical compositions comprising palonosetron and its pharmaceutically acceptable salts, in the form of a ready-to-use solution or a lyophilized form. Specific embodiments of the invention relate to stable pharmaceutical formulations of palonosetron and its pharmaceutically acceptable salts, wherein the formulation does not comprise a chelating agent or an antioxidant.
Type:
Application
Filed:
May 30, 2012
Publication date:
September 20, 2012
Applicants:
DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LIMITED
Abstract: Premixes of dexlansoprazole with pharmaceutical excipients, processes for preparing premixes, pharmaceutical formulations containing the premixes, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.
Type:
Application
Filed:
May 18, 2012
Publication date:
September 13, 2012
Applicants:
DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LIMITED
Abstract: The present invention relates to pharmaceutical compositions of antihistamine-decongestant combination. Specifically the invention relates to bilayered tablet formulation comprising antihistaminic decongestant combination. More specifically present invention relates to the novel polymorph of fexofenadine or pharmaceutically accepted salts thereof, with at least one decongestant in the form of bilayered tablet. The preferred polymorphs are polymorph A and polymorph X of fexofenadine hydrochloride.
Type:
Grant
Filed:
April 4, 2002
Date of Patent:
September 11, 2012
Assignees:
Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
Abstract: A hydrate of esomeprazole magnesium in the form of an amorphous solid is provided. Methods of preparation and use of, as well as formulation containing the hydrate of esomeprazole magnesium in the form of an amorphous solid are also provided.
Type:
Grant
Filed:
September 28, 2009
Date of Patent:
March 13, 2012
Assignees:
Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
Abstract: Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent.
Type:
Application
Filed:
October 17, 2011
Publication date:
February 16, 2012
Applicants:
DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LIMITED
Abstract: A 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.
Type:
Grant
Filed:
October 12, 2009
Date of Patent:
December 20, 2011
Assignees:
Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
Abstract: The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5?-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
June 30, 2006
Date of Patent:
December 20, 2011
Assignees:
Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
Abstract: Controlled release pharmaceutical compositions comprising ropinirole or pharmaceutically acceptable salts thereof, wherein embodiments have ropinirole embedded in a matrix comprising one or more polymers, and the composition in monolithic form or in multiparticulate form.
Type:
Application
Filed:
August 14, 2008
Publication date:
November 24, 2011
Applicants:
DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LIMITED
Abstract: A process for preparing crystalline Form A of tadalafil (I), comprising crystallization from a solution of tadalafil in a solvent comprising a C3-C7 ester, a ketone, dimethylformamide, dimethylsulfoxide, ethanol, acetonitrile, a chlorinated hydrocarbon, t-butanol, N,N-dimethylacetamide, dioxane, N-methyl pyrrolidone, or a mixture of any two or more thereof.
Type:
Grant
Filed:
October 26, 2005
Date of Patent:
November 22, 2011
Assignees:
Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
Inventors:
Eswaraiah Sajja, Venkata Naga Kali Vara Prasada Raju Vetukuri, Srinivas Reddy Ningam, Ravindra Vedantham, Rajyalakshmi Bodepudi
Abstract: Eszopiclone is prepared by reacting zopiclone with an enatiomerically pure di-p-toluoyl tartaric acid, recovering a solid salt, and reacting a solid salt with a base. Zopiclone is prepared by reacting 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]-pyrazine with 1-chlorocarbonyl-4-methylpiperazine hydrochloride.
Type:
Grant
Filed:
December 19, 2008
Date of Patent:
November 15, 2011
Assignees:
Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.,
Abstract: Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent.
Type:
Grant
Filed:
June 5, 2006
Date of Patent:
November 8, 2011
Assignees:
Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.,
Abstract: There is provided a process for preparing 21-acetyloxy-6-alpha-fluoro-pregna-1,4,9(11),16-tetraene-3,20-dione compound of Formula I, which comprises reacting 21-acetyloxy-pregna-1,3,5,9(11),16-pentaene-3-oxo acetate with a fluorinating agent.
Type:
Grant
Filed:
March 21, 2008
Date of Patent:
November 1, 2011
Assignees:
Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
Inventors:
Sergio Ferrino, Diego Torres, Vilas Dahanukar
Abstract: Voriconazole is prepared by a process comprising condensing 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazole-1-yl)ethanone with 4-chloro-6-ethyl-5-fluoropyrimidine, in a ketone, ether, aliphatic hydrocarbon, or aromatic hydrocarbon solvent, to give (2R,3S/2S,3R)-3-(4-chloro-5-fluoropyrimidin-6-yl)-2-(2,4-diflurophenyl)-1-(1H -1,2,4-triazole-1-yl)butan-2-ol.
Type:
Grant
Filed:
June 10, 2010
Date of Patent:
October 18, 2011
Assignees:
Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
Abstract: There are provided processes for making rivastigmine. In one embodiment, the process includes reacting S-(?)-[1-(3-hydroxyphenyl)ethyl]dimethylamine with N-ethyl-N-methyl carbamoyl chloride in the presence of an organic base to obtain a free base of rivastigmine.
Type:
Grant
Filed:
April 10, 2008
Date of Patent:
September 6, 2011
Assignees:
Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
Abstract: Novel bicyclic compounds of the formula (I), stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided: wherein R1, R2, m, and n are defined herein.
Type:
Grant
Filed:
September 3, 2009
Date of Patent:
August 2, 2011
Assignee:
Dr. Reddy's Laboratories Limited
Inventors:
Dibyendu De, Ish Kumar Khanna, Sivaram Pillarisetti
Abstract: There is provided a powder composition for use in a pharmaceutical product, the composition including a) 5(S)-(2?-hydroxyethoxy)-20(S)-CPT; at least one cyclodextrin; wherein 5(S)-(2?-hydroxyethoxy)-20(S)-CPT includes less than 5% of 5(R)-(2?-hydroxyethoxy)-20(S)-CPT. Preferably, in the powder composition, 5(S)-(2?-hydroxyethoxy)-20(S)-CPT is substantially free from said 5(R)-(2?-hydroxyethoxy)-20(S)-CPT.
Type:
Application
Filed:
May 27, 2008
Publication date:
July 21, 2011
Applicants:
DR. REDDY'S LABORATORIES LIMITED, DR. REDDY'S LABORATORIES, INC.